Mundipharma names new chief executive

13 December 2017

Mundipharma network of independent associated companies has appointed Alberto Martinez as president and chief executive of Mundipharma International, with immediate effect.

He succeeds Antony Mattessich, who has left the Mundipharma network after 12 years of service to pursue his career in the USA.

Dr Martinez will also focus on key strategic priorities that include expanding and diversifying the network’s product portfolio, where the network is open to new alliance opportunities at all stages of asset maturity across the commercial platforms of specialist-driven primary care, specialty care (including emergency care, oncology and biosimilars) and established brands.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK